Stock comparison
Alkermes
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALKS
Alkermes
Market cap
$6.13B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALKS | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 72B | RMD |
| Benjamin Graham | 74D | 75B | RMD |
| Philip Fisher | 58C | 75B | RMD |
| Peter Lynch | 44D | 58C | RMD |
| Joel Greenblatt | 51D | 47D | ALKS |
| Charlie Munger | 62D | 69B | RMD |
| Terry Smith | 60D | 73B | RMD |
Side-by-side metrics
| Metric | ALKS | RMD |
|---|---|---|
| Market cap | $6.13B | $30.18B |
| P/E (TTM) | 41.7x | 19.6x |
| EV/EBIT | 30.0x | 17.1x |
| ROIC (TTM) | 3.89% | 19.63% |
| Gross margin | 86.63% | 61.69% |
| Net margin | 9.78% | 27.44% |
| Revenue CAGR 5y | 5.89% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.9x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALKS leads on
- Gross margin86.63%vs 61.69%+29%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 0.9x+86%
- ROIC (TTM)19.63%vs 3.89%+80%
- Market cap$30.18Bvs $6.13B+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.